Biology of Chronic Lymphocytic Leukemia in Different Microenvironments. Clinical and Therapeutic Implications.

Hematology/Oncology Clinics of North America

Volumn 27, Issue 2, 2013, Pages 173-206

  Herishanu, Yair ^a   Katz, Ben Zion ^a   Lipsky, Andrew ^b   Wiestner, Adrian ^b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

B cell receptor signaling; Chronic lymphocytic leukemia; Microenvironment; Targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ATACICEPT; DASATINIB; EVEROLIMUS; FLUDARABINE; FOSTAMATINIB; IBRUTINIB; IDELALISIB; ISOSORBIDE; LENALIDOMIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PLERIXAFOR; RITUXIMAB; SORAFENIB; THALIDOMIDE;

ANTIGEN SPECIFICITY; APOPTOSIS; ATAXIA; BIOLOGY; CELL INTERACTION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; EUPHORIA; FOLLICULAR DENDRITIC CELL; HUMAN; IMMUNOSTIMULATION; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MACROPHAGE; MESENCHYMAL STROMA CELL; MONOCYTE; NEUTROPENIA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMATIC MUTATION; SOMNOLENCE; T LYMPHOCYTE; TUMOR MICROENVIRONMENT;

EID: 84875802229     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.01.002     Document Type: Review

References (237)

1. Caligaris-Cappio F., Hamblin T.J. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999, 17(1):399-408.
2. Hallek M., Fischer K., Fingerle-Rowson G., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174.
3. Panayiotidis P., Jones D., Ganeshaguru K., et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 1996, 92(1):97-103.
4. Lagneaux L., Delforge A., De Bruyn C., et al. Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells. Leuk Lymphoma 1999, 35(5-6):445-453.
5. Andreeff M., Darzynkiewicz Z., Sharpless T.K., et al. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980, 55(2):282-293.
6. Damle R.N., Temburni S., Calissano C., et al. CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 2007, 110(9):3352-3359.
7. Messmer B.T., Messmer D., Allen S.L., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115(3):755-764.
8. Herishanu Y., Perez-Galan P., Liu D., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117(2):563-574.
9. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001, 97(9):2777-2783.
10. Davids M.S., Deng J., Wiestner A., et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012, 120(17):3501-3509.
11. Patten P.E., Buggins A.G., Richards J., et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111(10):5173-5181.
12. Ghia P., Guida G., Stella S., et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003, 101(4):1262-1269.
13. Jaksic O., Paro M.M., Kardum Skelin I., et al. CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. Blood 2004, 103(5):1968-1969.
14. Quijano S., Lopez A., Rasillo A., et al. Association between the proliferative rate of neoplastic B cells, their maturation stage, and underlying cytogenetic abnormalities in B-cell chronic lymphoproliferative disorders: analysis of a series of 432 patients. Blood 2008, 111(10):5130-5141.
15. Smit L.A., Hallaert D.Y., Spijker R., et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007, 109(4):1660-1668.
16. Rui L., Schmitz R., Ceribelli M., et al. Malignant pirates of the immune system. Nat Immunol 2011, 12(10):933-940.
17. Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(7277):88-92.
18. Ghia P., Chiorazzi N., Stamatopoulos K. Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 2008, 264(6):549-562.
19. Stevenson F.K., Krysov S., Davies A.J., et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118(16):4313-4320.
20. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120(24):4684-4691.
21. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120(6):1175-1184.
22. Davids M.S., Brown J.R. Targeting the B cell receptor pathway in chronic lymphocytic leukemia. Leuk Lymphoma 2012, 53(12):2362-2370.
23. Fais F., Ghiotto F., Hashimoto S., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998, 102(8):1515-1525.
24. Tobin G., Thunberg U., Karlsson K., et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004, 104(9):2879-2885.
25. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194(11):1639-1647.
26. Klein U., Tu Y., Stolovitzky G.A., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194(11):1625-1638.
27. Damle R.N., Ghiotto F., Valetto A., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99(11):4087-4093.
28. Mockridge C.I., Potter K.N., Wheatley I., et al. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109(10):4424-4431.
29. Muzio M., Apollonio B., Scielzo C., et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112(1):188-195.
30. Lanham S., Hamblin T., Oscier D., et al. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003, 101(3):1087-1093.
31. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94(6):1840-1847.
32. Hamblin T.J., Davis Z., Gardiner A., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94(6):1848-1854.
33. Agathangelidis A., Darzentas N., Hadzidimitriou A., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012, 119(19):4467-4475.
34. Messmer B.T., Albesiano E., Efremov D.G., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004, 200(4):519-525.
35. Stamatopoulos K., Belessi C., Moreno C., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109(1):259-270.
36. Chu C.C., Catera R., Hatzi K., et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008, 112(13):5122-5129.
37. Binder M., Lechenne B., Ummanni R., et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS One 2010, 5(12):e15992.
38. Herve M., Xu K., Ng Y.S., et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005, 115(6):1636-1643.
39. Lanemo Myhrinder A., Hellqvist E., Sidorova E., et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008, 111(7):3838-3848.
40. Catera R., Silverman G.J., Hatzi K., et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008, 14(11-12):665-674.
41. Chiorazzi N., Efremov D.G. Chronic lymphocytic leukemia: a tale of one or two signals?. Cell Res 2012, 10.1038/cr.2012.152.
42. Chu C.C., Catera R., Zhang L., et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010, 115(19):3907-3915.
43. Clark E.A., Ledbetter J.A. How B and T cells talk to each other. Nature 1994, 367(6462):425-428.
44. Contri A., Brunati A.M., Trentin L., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005, 115(2):369-378.
45. Longo P.G., Laurenti L., Gobessi S., et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111(2):846-855.
46. Chen L., Widhopf G., Huynh L., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100(13):4609-4614.
47. Hivroz C., Geny B., Brouet J.C., et al. Altered signal transduction secondary to surface IgM cross-linking on B-chronic lymphocytic leukemia cells. Differential activation of the phosphatidylinositol-specific phospholipase C. J Immunol 1990, 144(6):2351-2358.
48. Petlickovski A., Laurenti L., Li X., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105(12):4820-4827.
49. Krysov S., Potter K.N., Mockridge C.I., et al. Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood 2010, 115(21):4198-4205.
50. Duhren-von Minden M., Ubelhart R., Schneider D., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489(7415):309-312.
51. Ubelhart R., Bach M.P., Eschbach C., et al. N-linked glycosylation selectively regulates autonomous precursor BCR function. Nat Immunol 2010, 11(8):759-765.
52. Zupo S., Isnardi L., Megna M., et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996, 88(4):1365-1374.
53. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101(12):4944-4951.
54. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348(18):1764-1775.
55. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351(9):893-901.
56. Orchard J.A., Ibbotson R.E., Davis Z., et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004, 363(9403):105-111.
57. Rassenti L.Z., Jain S., Keating M.J., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112(5):1923-1930.
58. Chen L., Apgar J., Huynh L., et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005, 105(5):2036-2041.
59. Chen L., Huynh L., Apgar J., et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008, 111(5):2685-2692.
60. Gobessi S., Laurenti L., Longo P.G., et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007, 109(5):2032-2039.
61. Bernal A., Pastore R.D., Asgary Z., et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001, 98(10):3050-3057.
62. Quiroga M.P., Balakrishnan K., Kurtova A.V., et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 2009, 114(5):1029-1037.
63. Deglesne P.A., Chevallier N., Letestu R., et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res 2006, 66(14):7158-7166.
64. Burger J.A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011, 2011:96-103.
65. Dal Bo M., Bomben R., Zucchetto A., et al. Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. Curr Pharm Des 2012, 18(23):3323-3334.
66. Bagnara D., Kaufman M.S., Calissano C., et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood 2011, 117(20):5463-5472.
67. Devereux S. Two-faced T cells in CLL. Blood 2011, 117(20):5273-5274.
68. Pizzolo G., Chilosi M., Ambrosetti A., et al. Immunohistologic study of bone marrow involvement in B-chronic lymphocytic leukemia. Blood 1983, 62(6):1289-1296.
69. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103(12):4389-4395.
70. Ghia P., Strola G., Granziero L., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002, 32(5):1403-1413.
71. Fluckiger A.C., Rossi J.F., Bussel A., et al. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992, 80(12):3173-3181.
72. Cuni S., Perez-Aciego P., Perez-Chacon G., et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004, 18(8):1391-1400.
73. Furman R.R., Asgary Z., Mascarenhas J.O., et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000, 164(4):2200-2206.
74. Romano M.F., Lamberti A., Tassone P., et al. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998, 92(3):990-995.
75. Kitada S., Zapata J.M., Andreeff M., et al. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 106(4):995-1004.
76. Hallaert D.Y., Jaspers A., van Noesel C.J., et al. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL; implications for therapeutic targeting of chemoresistant niches. Blood 2008, 112(13):5141-5149.
77. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998, 396(6711):580-584.
78. Dancescu M., Rubio-Trujillo M., Biron G., et al. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 1992, 176(5):1319-1326.
79. Trentin L., Cerutti A., Zambello R., et al. Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 1996, 87(8):3327-3335.
80. Foa R., Massaia M., Cardona S., et al. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood 1990, 76(2):393-400.
81. Reittie J.E., Yong K.L., Panayiotidis P., et al. Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 1996, 22(1-2):83-90. follow 186, color plate VI.
82. Buschle M., Campana D., Carding S.R., et al. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993, 177(1):213-218.
83. Panayiotidis P., Ganeshaguru K., Jabbar S.A., et al. Alpha-interferon (alpha-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro. Br J Haematol 1994, 86(1):169-173.
84. Chaouchi N., Wallon C., Goujard C., et al. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis. Blood 1996, 87(3):1022-1029.
85. Lotz M., Ranheim E., Kipps T.J. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994, 179(3):999-1004.
86. Fayad L., Keating M.J., Reuben J.M., et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001, 97(1):256-263.
87. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993, 177(4):925-935.
88. Beyer M., Kochanek M., Darabi K., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106(6):2018-2025.
89. Biancotto A., Dagur P.K., Fuchs J.C., et al. Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. Mod Pathol 2012, 25(2):246-259.
90. Gorgun G., Holderried T.A., Zahrieh D., et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005, 115(7):1797-1805.
91. Ramsay A.G., Johnson A.J., Lee A.M., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008, 118(7):2427-2437.
92. Ramsay A.G., Gribben J.G. The 3 Rs in CLL immune dysfunction. Blood 2010, 115(13):2563-2564.
93. Lagneaux L., Delforge A., Bron D., et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91(7):2387-2396.
94. Kurtova A.V., Balakrishnan K., Chen R., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114(20):4441-4450.
95. Ding W., Knox T.R., Tschumper R.C., et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116(16):2984-2993.
96. Ding W., Nowakowski G.S., Knox T.R., et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009, 147(4):471-483.
97. Ghosh A.K., Secreto C.R., Knox T.R., et al. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115(9):1755-1764.
98. Schulz A., Toedt G., Zenz T., et al. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica 2011, 96(3):408-416.
99. Ruan J., Hyjek E., Kermani P., et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin Cancer Res 2006, 12(19):5622-5631.
100. Orimo A., Gupta P.B., Sgroi D.C., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121(3):335-348.
101. Burger M., Hartmann T., Krome M., et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 2005, 106(5):1824-1830.
102. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
103. de la Fuente M.T., Casanova B., Moyano J.V., et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002, 71(3):495-502.
104. Redondo-Munoz J., Ugarte-Berzal E., Terol M.J., et al. Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia b cell survival through its hemopexin domain. Cancer Cell 2010, 17(2):160-172.
105. Redondo-Munoz J., Escobar-Diaz E., Samaniego R., et al. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 2006, 108(9):3143-3151.
106. Ringshausen I., Dechow T., Schneller F., et al. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004, 18(12):1964-1970.
107. Lee Y.K., Bone N.D., Strege A.K., et al. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 2004, 104(3):788-794.
108. Lee Y.K., Shanafelt T.D., Bone N.D., et al. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005, 19(4):513-523.
109. Gehrke I., Gandhirajan R.K., Poll-Wolbeck S.J., et al. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med 2011, 17(7-8):619-627.
110. Buggins A.G., Pepper C., Patten P.E., et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010, 70(19):7523-7533.
111. Herishanu Y., Gibellini F., Njuguna N., et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma 2011, 52(9):1758-1769.
112. Park C.S., Choi Y.S. How do follicular dendritic cells interact intimately with B cells in the germinal centre?. Immunology 2005, 114(1):2-10.
113. Chilosi M., Pizzolo G., Fiore-Donati L., et al. Routine immunofluorescent and histochemical analysis of bone marrow involvement of lymphoma/leukaemia: the use of cryostat sections. Br J Cancer 1983, 48(6):763-775.
114. Ratech H., Sheibani K., Nathwani B.N., et al. Immunoarchitecture of the " pseudofollicles" of well-differentiated (small) lymphocytic lymphoma: a comparison with true follicles. Hum Pathol 1988, 19(1):89-94.
115. Schmid C., Isaacson P.G. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994, 24(5):445-451.
116. Chilosi M., Pizzolo G., Caligaris-Cappio F., et al. Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia. Cancer 1985, 56(2):328-332.
117. Pedersen I.M., Kitada S., Leoni L.M., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100(5):1795-1801.
118. Burger J.A., Tsukada N., Burger M., et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96(8):2655-2663.
119. Tsukada N., Burger J.A., Zvaifler N.J., et al. Distinctive features of " nurselike" cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002, 99(3):1030-1037.
120. Nishio M., Endo T., Tsukada N., et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005, 106(3):1012-1020.
121. Schiemann B., Gommerman J.L., Vora K., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293(5537):2111-2114.
122. Schneider P., Takatsuka H., Wilson A., et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001, 194(11):1691-1697.
123. Mackay F., Schneider P., Rennert P., et al. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
124. Kern C., Cornuel J.F., Billard C., et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004, 103(2):679-688.
125. Novak A.J., Bram R.J., Kay N.E., et al. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. Blood 2002, 100(8):2973-2979.
126. Zhang W., Kater A.P., Widhopf G.F., et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2010, 107(44):18956-18960.
127. Krysov S., Dias S., Paterson A., et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood 2012, 119(1):170-179.
128. Deaglio S., Vaisitti T., Bergui L., et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005, 105(8):3042-3050.
129. Granziero L., Circosta P., Scielzo C., et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. Blood 2003, 101(5):1962-1969.
130. Moser B., Loetscher P. Lymphocyte traffic control by chemokines. Nat Immunol 2001, 2(2):123-128.
131. Burger J.A., Burger M., Kipps T.J. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94(11):3658-3667.
132. Mohle R., Failenschmid C., Bautz F., et al. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1). Leukemia 1999, 13(12):1954-1959.
133. Richardson S.J., Matthews C., Catherwood M.A., et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107(9):3584-3592.
134. Vaisitti T., Aydin S., Rossi D., et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010, 24(5):958-969.
135. Deaglio S., Vaisitti T., Aydin S., et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood 2007, 110(12):4012-4021.
136. Gunn M.D., Ngo V.N., Ansel K.M., et al. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998, 391(6669):799-803.
137. Burkle A., Niedermeier M., Schmitt-Graff A., et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B cell chronic lymphocytic leukemia. Blood 2007, 110(9):3316-3325.
138. Ticchioni M., Essafi M., Jeandel P.Y., et al. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene 2007, 26(50):7081-7091.
139. Reif K., Ekland E.H., Ohl L., et al. Balanced responsiveness to chemoattractants from adjacent zones determines B-cell position. Nature 2002, 416(6876):94-99.
140. Till K.J., Lin K., Zuzel M., et al. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 2002, 99(8):2977-2984.
141. Chunsong H., Yuling H., Li W., et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 2006, 177(10):6713-6722.
142. Lopez-Giral S., Quintana N.E., Cabrerizo M., et al. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. J Leukoc Biol 2004, 76(2):462-471.
143. Menten P., Wuyts A., Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002, 13(6):455-481.
144. Burger J.A., Quiroga M.P., Hartmann E., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113(13):3050-3058.
145. Zucchetto A., Benedetti D., Tripodo C., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009, 69(9):4001-4009.
146. Sivina M., Hartmann E., Kipps T.J., et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011, 117(5):1662-1669.
147. Hewamana S., Lin T.T., Rowntree C., et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 2009, 27(5):763-769.
148. Fruman D.A., Bismuth G. Fine tuning the immune response with PI3K. Immunol Rev 2009, 228(1):253-272.
149. Cuesta-Mateos C., Lopez-Giral S., Alfonso-Perez M., et al. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Exp Hematol 2010, 38(9):756-764. 764.e1-4.
150. Hanada M., Delia D., Aiello A., et al. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82(6):1820-1828.
151. Kitada S., Andersen J., Akar S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998, 91(9):3379-3389.
152. Balogh Z., Reiniger L., Rajnai H., et al. High rate of neoplastic cells with genetic abnormalities in proliferation centers of chronic lymphocytic leukemia. Leuk Lymphoma 2011, 52(6):1080-1084.
153. Delmer A., Ajchenbaum-Cymbalista F., Tang R., et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995, 85(10):2870-2876.
154. Solvason N., Wu W.W., Kabra N., et al. Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes. J Exp Med 1996, 184(2):407-417.
155. Igawa T., Sato Y., Takata K., et al. Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma. Cancer Sci 2011, 102(11):2103-2107.
156. Bichi R., Shinton S.A., Martin E.S., et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A 2002, 99(10):6955-6960.
157. Gorgun G., Ramsay A.G., Holderried T.A., et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 2009, 106(15):6250-6255.
158. Phillips J.A., Mehta K., Fernandez C., et al. The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 1992, 52(2):437-443.
159. Raveche E.S., Salerno E., Scaglione B.J., et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007, 109(12):5079-5086.
160. Calin G.A., Dumitru C.D., Shimizu M., et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002, 99(24):15524-15529.
161. Klein U., Lia M., Crespo M., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17(1):28-40.
162. Wen X., Zhang D., Kikuchi Y., et al. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus. Eur J Immunol 2004, 34(10):2740-2749.
163. Zapata J.M., Krajewska M., Morse H.C., et al. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc Natl Acad Sci U S A 2004, 101(47):16600-16605.
164. Bertilaccio M.T., Scielzo C., Simonetti G., et al. A novel Rag2-/-gammac-/-xenograft model of human CLL. Blood 2010, 115(8):1605-1609.
165. Sun X., Herman S.E.M., Hsieh M.M., et al. The NSG - human CLL xenograft model recapitulates the human lymph node microenvironment in regards to B-cell activation and tumor proliferation. ASH Annual Meeting Abstracts. Blood 2011, 118(21). [abstract no. 973].
166. Durig J., Ebeling P., Grabellus F., et al. A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. Cancer Res 2007, 67(18):8653-8661.
167. Herman S.E., Sun X., Buggy J.J., et al. The Bruton tyrosine kinase inhibitor, PCI-32765, inhibits activation and proliferation of human chronic lymphocytic leukemia cells in the NSG xenograph mouse model of the tissue microenvironment. ASH Annual Meeting Abstracts. Blood 2011, 118(21). [abstract no. 596].
168. Aydin S., Grabellus F., Eisele L., et al. Investigating the role of CD38 and functionally related molecular risk factors in the CLL NOD/SCID xenograft model. Eur J Haematol 2011, 87(1):10-19.
169. Buchner M., Brantner P., Stickel N., et al. The microenvironment differentially impairs passive and active immunotherapy in chronic lymphocytic leukaemia - CXCR4 antagonists as potential adjuvants for monoclonal antibodies. Br J Haematol 2010, 151(2):167-178.
170. Andritsos L., Byrd J.C., Jones J.A., et al. Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2010, 116(21). [abstract no. 2450].
171. Kofler D.M., Gawlik B.B., Elter T., et al. Phase 1b trial of atacicept, a recombinant protein binding BLyS and APRIL, in patients with chronic lymphocytic leukemia. Leukemia 2012, 26(4):841-844.
172. Byrd J.C., Furman R.R., Coutre S., et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naive (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study. ASH Annual Meeting Abstracts. Blood 2012, 120(21). [abstract no. 189].
173. Coutre S.E., Byrd J.C., Furman R.R., et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2011, 29(Suppl). [abstract no. 6631].
174. Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585.
175. de Rooij M.F., Kuil A., Geest C.R., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119(11):2590-2594.
176. Ponader S., Chen S.S., Buggy J.J., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119(5):1182-1189.
177. Hantschel O., Rix U., Schmidt U., et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007, 104(33):13283-13288.
178. Amrein L., Hernandez T.A., Ferrario C., et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008, 143(5):698-706.
179. Veldurthy A., Patz M., Hagist S., et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 2008, 112(4):1443-1452.
180. McCaig A.M., Cosimo E., Leach M.T., et al. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011, 153(2):199-211.
181. Amrein P.C., Attar E.C., Takvorian T., et al. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 2011, 17(9):2977-2986.
182. Mocsai A., Ruland J., Tybulewicz V.L. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010, 10(6):387-402.
183. Gobessi S., Laurenti L., Longo P.G., et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009, 23(4):686-697.
184. Hoellenriegel J., Coffey G.P., Sinha U., et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012, 26(7):1576-1583.
185. Suljagic M., Longo P.G., Bennardo S., et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010, 116(23):4894-4905.
186. Herman S.E., Barr P.M., McAuley E.M., et al. Fostamatinib inhibits BCR signaling, and reduces tumor cell activation and proliferation in patients with relapsed refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts. Blood 2012, 120(21). [abstract no. 2882].
187. Kyttaris V.C. Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012, 6:245-250.
188. Buggy J.J., Elias L. Bruton tyrosine kinase (BTK) and its role in B-cell malignancy. Int Rev Immunol 2012, 31(2):119-132.
189. Tsukada S., Saffran D.C., Rawlings D.J., et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72(2):279-290.
190. Herman S.E., Gordon A.L., Hertlein E., et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117(23):6287-6296.
191. Advani R.H., Buggy J.J., Sharman J.P., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012, 31(1):88-94.
192. Herman S.E., Gordon A.L., Wagner A.J., et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116(12):2078-2088.
193. Chapman C.M., Sun X., Roschewski M., et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012, 18(7):1979-1991.
194. Herman S.E., Lapalombella R., Gordon A.L., et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011, 117(16):4323-4327.
195. Hoellenriegel J., Meadows S.A., Sivina M., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118(13):3603-3612.
196. Lannutti B.J., Meadows S.A., Herman S.E., et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117(2):591-594.
197. Plate J.M. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation. Leuk Lymphoma 2004, 45(8):1519-1529.
198. Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282(5392):1318-1321.
199. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91(2):231-241.
200. Hahn-Windgassen A., Nogueira V., Chen C.C., et al. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J Biol Chem 2005, 280(37):32081-32089.
201. Brunet A., Bonni A., Zigmond M.J., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96(6):857-868.
202. Hirai H., Sootome H., Nakatsuru Y., et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010, 9(7):1956-1967.
203. Gills J.J., Dennis P.A. Perifosine: update on a novel Akt inhibitor. Curr Oncol Rep 2009, 11(2):102-110.
204. Kay J.E., Kromwel L., Doe S.E., et al. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991, 72(4):544-549.
205. Decker T., Hipp S., Ringshausen I., et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003, 101(1):278-285.
206. Decker T., Sandherr M., Goetze K., et al. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009, 88(3):221-227.
207. Zent C.S., LaPlant B.R., Johnston P.B., et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010, 116(9):2201-2207.
208. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134.
209. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
210. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
211. Messmer D., Fecteau J.F., O'Hayre M., et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011, 117(3):882-889.
212. Huber S., Oelsner M., Decker T., et al. Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011, 25(5):838-847.
213. Fecteau J.F., Bharati I.S., O'Hayre M., et al. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med 2012, 18(1):19-28.
214. Lopez-Guerra M., Xargay-Torrent S., Perez-Galan P., et al. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia 2012, 26(6):1429-1432.
215. Pepper C., Thomas A., Hoy T., et al. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 1999, 107(3):611-615.
216. O'Brien S.M., Cunningham C.C., Golenkov A.K., et al. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 2005, 23(30):7697-7702.
217. O'Brien S., Moore J.O., Boyd T.E., et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007, 25(9):1114-1120.
218. O'Brien S., Moore J.O., Boyd T.E., et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009, 27(31):5208-5212.
219. Nguyen M., Marcellus R.C., Roulston A., et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 2007, 104(49):19512-19517.
220. O'Brien S.M., Claxton D.F., Crump M., et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113(2):299-305.
221. Vogler M., Butterworth M., Majid A., et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009, 113(18):4403-4413.
222. Mason K.D., Khaw S.L., Rayeroux K.C., et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009, 23(11):2034-2041.
223. Roberts A.W., Seymour J.F., Brown J.R., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012, 30(5):488-496.
224. Balakrishnan K., Burger J.A., Wierda W.G., et al. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009, 113(1):149-153.
225. James D.F., Castro J.E., Loria O., et al. AT-101, a small molecule Bcl-2 antagonist, in treatment naïve CLL patients (pts) with high risk features; preliminary results from an ongoing phase I trial. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006, 24(18S):6605.
226. Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006, 7(10):988-994.
227. Frenzel L.P., Patz M., Pallasch C.P., et al. Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis. Br J Haematol 2011, 152(2):191-200.
228. Chanan-Khan A., Miller K.C., Musial L., et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006, 24(34):5343-5349.
229. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111(11):5291-5297.
230. Badoux X.C., Keating M.J., Wen S., et al. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood 2011, 118(13):3489-3498.
231. Andritsos L.A., Johnson A.J., Lozanski G., et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008, 26(15):2519-2525.
232. Aue G., Njuguna N., Tian X., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94(9):1266-1273.
233. Chanan-Khan A., Miller K.C., Lawrence D., et al. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011, 117(10):2127-2135.
234. Ramsay A.G., Clear A.J., Fatah R., et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120(7):1412-1421.
235. Aue G., Pittaluga S., Liu D., et al. Correlates of lenalidomide induced immune stimulation and response in CLL: analysis in patients on treatment. Blood (ASH Annual Meeting Abstracts). Blood 2011, 118(21):979.
236. Wu L., Adams M., Carter T., et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14(14):4650-4657.
237. Masood A., Chitta K., Paulus A., et al. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol 2011, 10.1111/j.1365-2141.2011.08984.x.